Gastrointestinal Cancer News

Dietary exposure to aflatoxin, or toxins produced by fungi affecting certain crops, may increase the risk for gallbladder cancer, according to new research.

Weight loss 5 years after colorectal cancer diagnosis appeared associated with lower long-term survival, study data showed.

MADRID — Adjuvant treatment with imatinib improved outcomes among patients with high-risk gastrointestinal stromal tumors, according to final results of a randomized phase 3 trial presented at the European Society for Medical Oncology Congress.

MADRID — Pembrolizumab demonstrated promising activity in patients with pretreated recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the KEYNOTE-059 trial presented at the European Society for Medical Oncology Congress.

MADRID — Hybrid minimally invasive esophagectomy reduced incidence of major morbidity compared with open esophagectomy for patients with esophageal cancer, according to long-term results from a randomized, controlled phase 3 trial presented at the European Society for Medical Oncology Congress.

Two scientists from NCI will receive the Lasker-DeBakey Clinical Medical Research Award.

General practitioners who were notified about which of their adult patients were not current with their colorectal cancer screening resulted in a small but significant increase in patients undergoing fecal immunochemical tests within 1 year, according to study findings recently published in JAMA.

Mailed outreach invitations for colonoscopy or fecal immunochemical testing both increased the percentage of patients screened for colon cancer over 3 years, but the colonoscopy outreach was more effective, according to the results of a randomized controlled trial.

The FDA has granted 510(k) clearance to add Barrett’s esophagus with low-grade dysplasia to the label of CSA Medical’s truFreeze liquid nitrogen cryotherapy spray system, the company announced.

The addition of cetuximab to concurrent chemoradiation failed to improve survival in patients with esophageal cancer, according to results from the randomized, multicenter NRG-RTOG 0436 phase 3 trial.